Rapid delivery of inhaled treatment is a desirable attribute of most aerosol inhalation devices. We aimed to compare the delivered dose output rate of production equivalent InnoSpire Go nebulizers with an existing mesh nebulizer using 2 drugs at their respective fill volumes with an adult breathing pattern, and to establish typical treatment times with each volume of drug. Three of each nebulizer brand (InnoSpire Go, and MicroAir U22) were tested in triplicate delivering 2.5 mL of 5 mg/2.5 mL salbutamol sulphate and 2 mL of 0.5 mg/2 mL ipratropium bromide to a filter with a breathing simulator set with an adult breathing pattern (500 mL tidal volume, 1:1 inhalation:exhalation ratio, 15 breaths per minute). At treatment completion, elutions from filters and nebulizers were analyzed by high performance liquid chromatography. Delivered dose output rates to filter for the InnoSpire Go were 0.511 mg/min and 0.063 mg/min for salbutamol sulphate and ipratropium bromide, respectively, and 0.256 and 0.038 mL/min, respectively, for the MicroAir U22. Residual volumes were 0.02 mL and 0.01 mL, respectively, for the InnoSpire Go nebulizer, compared with 0.27 and 0.24 mL, respectively, for the MicroAir U22 nebulizer. Treatment times were 4.7 minutes and 3.7 minutes, respectively, for the InnoSpire Go nebulizer and 7.0 and 4.6 minutes, respectively, for the MicroAir U22. The dose delivery rates, residual volumes, output to filters, and treatment times found using the InnoSpire Go nebulizer compared favourably with the other mesh nebulizer. Aerosol particle size output also needs to be assessed to determine overall delivery efficiency.